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Antiretroviral therapy (ART) has increased the life span of the people living with HIV (PLHIV), but their virological and
immunological outcomes are not well documented in Nepal.The study was conducted at a tertiary care center including 826 HIV-1
seropositive individuals undergoing ART for at least six months. Plasma viral load (HIV-1 RNA) was detected by Real Time PCR
and CD4+ T-lymphocyte (CD4+) counts were estimated by flow cytometry. The mean CD4+ count of patients was 501 (95% CI
= 325–579) cells/cumm, but about 35% of patients had CD4+ T cell counts below 350 cells/cumm. With increasing age, average
CD4+ count was found to be decreasing (𝑝 = 0.005). Of the total cases, 82 (9.92%) were found to have virological failure (viral
load: >1000 copies/ml). Tenofovir/Lamivudine/Efavirenz (TDF/3TC/EFV), the frequently used ART regimen in Nepal, showed
virological failure in 11.34% and immunological failure in 37.17% of patients. Virological failure rate was higher among children <
15 years (14.5%) (𝑝 = 0.03); however, no association was observed between ART outcomes and gender or route of transmission.
The study suggests there are still some chances of virological and immunological failures despite the success of highly active ART
(HAART).
1. Background
Theepidemic of human immunodeficiency virus type 1 (HIV-
1) in Nepal is dynamic and concentrated among key popula-
tions at higher risk like people who inject drug (PWID), men
who have sex with men (MSM) and transgender people, sex
workers (SW), andmale labormigrants [1]. In 2015, estimated
HIV prevalence was 0.2% with estimated cases and reported
cases being 39,249 and 26,702, respectively [2]; however, the
prevalence data of HIV drug resistance has not yet been
available in Nepal. According to recent data, 11089 people
living with HIV (PLHIV) were on ART. Of them, 8003 were
on regular first-line regimens, 2944 on substituted first-line
regimens, and 142 on second-line regimens. Until July of 2015,
2089 cases of AIDS related death have been reported [2].
The primary goal of ART is to suppress HIV-1 RNA lower
than the detection level (LDL) of the assay within six months
on treatment and restore immunologic function, to reduce
morbidity andmortality, to reduce vertical transmission, and
to improve overall quality of life [3]. However, there are still
unresolved problems including early mortality, incomplete
responses, variations in ART outcomes, lack of universal
consensus to define treatment failures and time to start ART,
drug resistance, and loss to follow-ups [4]. Though HIV-1
RNA testing is the gold standard to monitor patients on ART,
due to costs and technical demands needed for it, CD4+ T cell
measurements are recommended for resource-poor settings
[5]. Due to the lack of HIV-1 RNA monitoring in resource-
poor settings, patients from these areas are supposed to
continue on first-line ART until virological failure progresses
to a 50%decrease inCD4+ T cell count (immunologic failure)
or the recurrence of symptomatic HIV disease (clinical
failure). Even then, clinicians may delay switching to second-
line therapy, due to the limited availability of second-line
medications and the poor specificity of CD4+ T cell counts
and clinical symptoms for predicting virological failure [6].
PlasmaHIV-1 RNA (viral load) testing quantifies theHIV
viral burden in the plasma. The viral load is a standard tool
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used to monitor treatment response in patients taking ART
and, in conjunction with the CD4+ T cell count, to assess
HIV progression. In some situations, viral load may factor
into decisions to initiate or change ART [7]. Studies have
shown that patients who have high plasma viral loads have
an increased risk of progression to symptomatic disease and
AIDS compared with patients who have low or undetectable
levels [8].
In Nepal, ART service was established in 2004 and
viral load facility was started in 2009 through National
Public Health Laboratory (NPHL). Phased scale-up has been
planned to efficiently and successfully expand viral load test-
ing services, taking into account the targets for enrollment of
PLHIV intoARTprogram. Based on the recommendations of
Consolidated Treatment Guidelines ofWorld Health Organi-
zation (WHO) and National Consolidated guideline on HIV
prevention, treatment, and care, Nepal is at the incipient stage
of HIV drug resistance andmonitoring of early warning indi-
cators [9]. Considering the expanding ART services in the
country including the drug resistance surveillance, this study
was conducted to establish baseline information on virolog-
ical and immunological status of the PLHIV receiving ART
for more than six months from various regions of Nepal, so
that it could facilitate the drug resistance surveillance across
the country by providing the insight into the outcome of ART.
2. Methodology
2.1. Study Design. A descriptive cross-sectional study was
conducted at National Public Health Laboratory from
November 2013 to June 2015. Patients from four major ART
service centers of Nepal, Teku ART Center, Kathmandu;
Western Regional Hospital ART Center, Pokhara; Chitwan
Hospital ART Center, Chitwan; and Lumbini Zonal Hospital
ART Center, Butwal, were enrolled.
2.2. Ethical Approval and Patient Recruitment. Ethical
approval of the study protocol was obtained from Nepal
Health Research Council and 826 patients were recruited
after obtaining written informed consent. HIV infected
individuals under ART for a minimum of six months
(referred to NPHL and other sites for HIV viral load testing)
and meeting the study criteria were enrolled.
2.3. Patient Data Collection. A standard data collection ques-
tionnaire was completed for each patient prior to sample col-
lection. Patient’s data including age, sex, ART sites, duration
of ART treatment, and ART regimens used were collected at
the sample collection site. The data were verified by using
the ART center database maintained at ART sites as well as
NPHL.
2.4. Sample Collection and Preparation. Blood sample (5mL)
was collected by registered laboratory technicians/technolo-
gists/nurses using BD K3EDTA Vacutainers and disposable
needles. The sample was divided into two separate vials: one
for CD4+ T cell count and the other for HIV-1 viral load test-
ing. For the latter, the tube with whole blood was centrifuged
at 1500 RPM for 10min, and plasma was separated, aliquoted,
and stored at −20∘C/−80∘C. Plasma samples separated in the
peripheral centers were stored at −20∘C andwere transported
to NPHL on the same day of sample collection, where the
plasma samples were stored at −80∘C until analysis.
2.5. Viral RNA Extraction and Plasma Viral Load Quantifica-
tion. HIV-1 RNAwas extracted by using QIAampViral RNA
Mini Kit (QIAGEN GmbH, Hilden, Germany) following the
manufacturer’s protocol.The eluted RNAwas stored at−80∘C
until RNA quantification. HIV-1 RNA was quantified by Real
Time PCR using artus HI Virus-1 RG RT-PCR Kit (QIAGEN
GmbH, Hilden, Germany) and Corbett Rotor-Gene 6000
Real Time PCR system. The PCR conditions were set for
denaturation 95∘C/30 seconds, annealing 50∘C/60 seconds,
and elongation 72∘C/30 seconds. A range of standards (10,
100, 1,000, and 10,000 IU/𝜇L) provided with the kits were
used to develop standard curve for the quantification of the
viral load copies per mL. Internal control was used to control
the RNA isolation procedure and to check for possible PCR
inhibition.
2.6. CD4+ T-Lymphocyte Estimation by Flow Cytometry. The
enumeration of CD4+ T lymphocytes was carried out by
flow cytometry (FACS Calibur, BD Biosciences, San Jose,
CA, USA) using the anticoagulated whole blood following
themanufacturer’s protocol. Tru-COUNT reagent containing
monoclonal antibodies for CD3, CD45, and CD4 labelled
with fluorescent dyes (PE, PerCP, and FITC, resp.) was mixed
with anticoagulated whole blood and red blood cells were
lysed with lysing solution before enumeration. BD MultiSET
software (BDBiosciences) was used to determine the absolute
CD4+ T cell counts.
2.7. Statistical Analysis. All the data were recorded in
Microsoft Excel 2013. The statistical analysis was carried out
by using SPSS 17.0 software and “Openepi” online software.
CD4+ T cell count < 350/cumm and viral load > 1000
copies/mL after six months of ART treatment were consid-
ered as cutoff for immunological and virological failures,
respectively. The outcome was analyzed with respect to age,
sex, route of transmission of HIV infection, and duration of
ART by using Chi-square test and ANOVA.
3. Results
The study comprised a total of 826 PLHIV under ART
for at least six months from different ART referral sites
of the country; out of them 419 were males and 407 were
females with male-to-female ratio of 1.03. The mean time
duration of ART treatment was 59.7 months. The patients
were representative of almost all regions of the country. The
number of samples collected from the referral sites is shown
in Figure 1.
3.1. Immunological Status of the PLHIV in Nepal. Overall
immunological status of the patients after taking ART for at
least six months was above the threshold line recommended
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Figure 1: Sample distribution according to sex and referral sites. BH:
Bharatpur Hospital, LZH: Lumbini Zonal Hospital, STH: Sukraraj
Tropical Hospital, andWRH:Western Regional Hospital. STH is the
largest ART service site in Nepal.
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Figure 2: Mean CD4 count of the patients after a duration of six
months or more of ART treatment. Error bar shows the standard
error of mean (SEM).
for ART startup, that is, 500 cells/cumm (mean CD4+ T cell
count = 501 cells/cumm; 95% confidence interval (CI) = 325–
579 cells/cumm). With increasing age, the average CD4+ T
cell count was found to be decreasing (ANOVA, 𝑝 = 0.0005).
Average CD4+ T cell count was 789 cells/cumm (95% CI;
630–947) in children below 15 years and 440 cells/cumm
(95% CI; 365–514) in PLHIV more than 15 years (Figure 2).
3.2. Virological Outcomes of the ART in PLHIV in Nepal.
Out of total 826 cases, 744 patients were found to have
suppressed (<1000 copies/mL) HIV-1 viral RNA level (viral
load), whereas 82 (9.92%) patients had shown virological
failure (>1000 copies/mL). 129 (15.6% of total) patients had
detectable viral load copies which were still below the thresh-
old considered for virological failure.The average HIV-1 viral
load was the highest (10,794 copies/mL) in the age group of
0–9 years (ANOVA, 𝑝 = 0.628 by between-group analysis)
though statistically insignificant (Figure 3). In the children
below 15 years, the frequency of virological failurewas slightly
higher (14.5%) than the overall rate (Table 1). There was
no significant association between virological outcomes in
different sex of patients and routes of transmission (Table 1).
Table 1: Virological outcome of patients under ART based on age,
sex, and route of transmission. Compared to adults, more numbers
of children below 15 years were found to have virological failure.
Category Total cases Virologicalfailure (%)
Children versus adult (𝑝 = 0.03)
Children < 15 years 96 14 (14.5)
Adults 730 68 (9.3)
Sex difference (𝑝 = 0.18)
Male 419 46 (10.9)
Female 407 36 (8.8)
Route of transmission (𝑝 = 0.4)
Intravenous 70 6 (8.5)
Percutaneous 756 76 (10)
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Figure 3: Mean viral load of patients (of different age groups) after
six months or more of ART treatment. Error bar shows the standard
error of mean (SEM).
3.3. Correlation between Virological and Immunological Status
of Patients under ART. We found no significant correlation
between virological and immunological status of the patients
based on absolute means comparison (𝑝 = 0.72). To address
the fluctuating values of viral load, we compared different
categories of CD4+ T cell levels and viral load levels, where
we observed significant association between virological and
immunological parameters (𝑝 = 0.028) with reciprocal
relationship between them (Tables 2 and 3; Figure 4).
3.4. Response of Commonly Used ART Regimen among PLHIV
in Nepal. We compared the virological and immunological
outcomes of different ART regimens currently being pre-
scribed in Nepal (Tables 4 and 5). Efavirenz based regimens
were found less effective than Nevirapine based regimens
for virological suppression (Figure 5). Among the com-
mon ART combination, Tenofovir/Lamivudine/Nevirapine
(TDF/3TC/NVP) was found to be most effective in terms
of virological response showing only 7.14% virological failure
rate (Table 4). TDF/3TC/EFV, the most commonly used
ART regimen in Nepal, had 11.34% virological and 37.02%
immunological failure rates (Figure 6). ABC/3TC/EFV was
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Table 2: Relationship between virological and immunological status of the patients under ART. The mean CD4+ T cell counts for patients
with different viral load levels were compared and the difference was found statistically insignificant (Pearson correlation, 𝑝 = 0.172).
Viral load group
(copies/mL)
Number of patients
(%)
Mean CD4+ T cell
count (95% CI),
cells/cumm
<400 615 (74.46%) 510 (485–536)
400–1000 129 (15.61%) 470 (424–516)
>1000 82 (9.93%) 480 (395–565)
Table 3: Virological status in different CD4+ T cell count groups. The number and the percentages of the patients out of total patients in
the designated CD4+ T cell count groups. With increasing CD4+ T cell count, the percentage of patients with virological suppression was
reported to be increasing (Pearson correlation, 𝑝 = 0.028). VL: viral load.
CD4 count
cells/cumm
Number of patients
in the group
Number of patients with
VL < 400
copies/mL (%)
VL = 400–1000
copies/mL (%)
VL > 1000
copies/mL (%)
0–100 26 14 (53.8%) 5 (19.23%) 7 (26.9%)
101–200 61 38 (62.3%) 13 (21.31%) 10 (16.39%)
201–350 199 150 (75.4%) 32 (16.08%) 17 (8.54%)
351–500 212 162 (76.4%) 28 (13.20%) 22 (10.37%)
>500 328 251 (76.5%) 51 (15.54%) 26 (7.92%)
Total 826 615 (74.46%) 129 (15.61%) 82 (9.93%)
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Figure 4: Correlation between CD4+ T cell counts and HIV-1 viral
load.Themean viral load copies/mL for different CD4 count groups
are plotted in the graph. Inverse relationship was observed; with
increasing CD4 counts, viral load was found to be decreasing. Error
bar showing the SEM.
found to be the least effective in terms of both immunological
and virological response (Tables 4 and 5; Figure 6).
4. Discussion and Conclusion
Since the inception of ART for HIV treatment in 2004,
there has been a substantial increment of people on ART
and improvement of their health status [10]. With this, the
potential for widespread emergence and transmission of HIV
drug resistance has been a major concern. HIV drug resis-
tance surveillance program has been integrated into Nepal’s
national HIV program to emphasize the core elements of
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Figure 5: Comparison of selected common drugs used for ART in
Nepal. 3TC: Lamivudine; NVP: Nevirapine; EFV: Efavirenz; AZT:
Zidovudine.Nevirapine based regimenswere found to suppress viral
load more effectively in comparison to Efavirenz based regimens
(𝑝 = 0.04).
EarlyWarning Indictors (EWI)monitoring and conductHIV
drug resistance survey throughout the country from 2014 to
2020 [11]. The findings of this study give an insight into the
situation of people living with HIV (PLHIV) in Nepal in
terms of immunological and virological status after ART.
The ART regimens used in Nepal had shown good
response in reducing the HIV-1 viral load. The failure rate
observed in our study was concordant with the various
studies conducted in other countries [12–15]. The overall
9.92% of virological failure may be attributed to various
factors like poor adherence to the drug, timely unavailability
BioMed Research International 5
Table 4: Virological status of the patients under different ART regimens. The table shows the number of patients treated with different ART
regimens and found to have different levels of viral load (detection limit of the assay was 400 copies/mL). VL: viral load. EFV: Efavirenz, 3TC:
Lamivudine, NVP: Nevirapine, AZT: Zidovudine, and TDF: Tenofovir.
ART regimens Number of patients with VL failure rate (%)
VL < 400 copies/mL VL = 400–1000 copies/mL VL > 1000 copies/mL Total
AZT/3TC/NVP 111 37 15 163 9.2
TDF/3TC/NVP 206 15 17 238 7.14
TDF/3TC/EFV 232 65 38 335 11.34
AZT/3TC/EFV 26 4 4 34 11.76
ABC/3TC/EFV 11 4 4 19 21.05
Other 29 4 4 37 10.81
Total 615 129 82 826 9.92
Table 5: Immunological status of the patients under different ART regimens in Nepal. The table shows the number of patients treated with
different ART regimens and having designated CD4+ T cell count groups. In the parentheses are the percentages out of total patients with the
particular regimens.
ART regimen Total cases Number and percentage of patients with given CD4
+ T cell count (cells/cumm)
<100 100–200 201–350 >350–500 >500 <350
AZT/3TC/NVP 163 4 (2.45%) 11 (6.75%) 41 (25.15%) 35 (21.74%) 72 (44.17%) 56 (34.36%)
TDF/3TC/NVP 238 7 (2.94%) 18 (7.56%) 54 (22.68%) 61 (25.63%) 98 (41.18%) 79 (33.2%)
TDF/3TC/EFV 335 13 (3.88%) 24 (7.16%) 87 (25.97%) 95 (28.36%) 116 (34.63%) 124 (37.02%)
AZT/3TC/EFV 34 0 2 (5.88%) 7 (20.59%) 9 (26.47%) 16 (47.06%) 9 (26.47%)
ABC/3TC/EFV 19 0 3 (15.79%) 4 (21.05%) 3 (15.79%) 9 (47.37%) 7 (36.84%)
Other 37 2 (5.41%) 3 (8.11%) 6 (16.22%) 9 (24.32%) 17 (45.95%) 11 (29.73%)
Total 826 26 (3.14%) 61 (7.38%) 199 (24.09%) 212 (26.67%) 256 (30.99%) 286 (34.62%)
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Figure 6: Virological and immunological failure rates with different
ART regimes. The blue bar shows the percentage of patients treated
with given regimens and having reported to have CD4+ T cell
counts less than 350 cells/cumm. CD4+ T cell count less than 350
cells/cumm was considered borderline to determine eligibility for
starting the ART before implementation of the new consolidated
guideline for treatment of HIV 2013. Red bar shows the number
of patients treated with the given regimen shown to have viral load
more than 1000 copies/mL. EFV: Efavirenz, 3TC: Lamivudine, NVP:
Nevirapine, AZT: Zidovudine, TDF: Tenofovir, and ABC: Abacavir.
of drugs, difference in baseline viral load and CD4 counts,
HIV transmission route, duration of treatment, nutritional
status, and support to the patients [13, 16]. We analyzed and
compared the virological and immunological responses in
different age, sex, and route of transmission.The data showed
that children were more susceptible to the virological failures
(𝑝 = 0.03) compared to adults. However, no significant
difference was observed in terms of gender and route of
transmission. The immunological recovery was observed in
62.98% to 73.53% of the total study population depending
upon the combination of regimens used. Similarly, virological
suppression was manifested in 78.95% to 92.86% of the
patients. Out of different regimens, TDF/3TC/NVP and
AZT/3TC/NVP had better immunological and virological
response among Nepalese PLHIV. These results are concor-
dant with Chinese population, where 12.1% failure rate was
observed with 3TC combined drugs [13].
Our study showed better outcome of Nevirapine based
regimen than Efavirenz based regimen (𝑝 = 0.04) in line
with study results from India [17]. Keeping in view the similar
nature of HIV epidemics, social cultural, and geographical
similarities between Nepal and India, this comparison seems
realistic. So, we can infer from these two studies that Nevi-
rapine based combinations are either better or equivalent to
the Efavirenz based regimens (at least in our setting) which
are relatively expensive [17]. Although a separate study in
Botswana showed better response with Efavirenz based drugs
than Nevirapine based drugs [18], difference might be due to
discrepancy in prevalence of HIV-1 subtypes in Nepal and
Botswana. We did not find significant effect of duration of
ART on the virological and immunological outcomes, which
was in line with a study conducted in India [19].
There are some limitations in our study; we could not
measure the baseline values, the studywas conducted in short
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duration (long term impact needs longer prospective study),
drug resistance testing facility has not been yet available in
the country, the patient’s information was taken from the
records retrospectively, and the failure rates were determined
based on a single point testing of CD4+ T cell and viral load
after six months of ART treatment. Despite these limitations,
this is the first attempt in Nepal to explore and extract
baseline information on the immunological and virological
status of Nepalese patients under ART. This information will
certainly be useful for theHIV/ART programs in the country.
Moreover, we emphasize comprehensive prospective studies
including baseline survey, clinical situation of patients, drug
resistance testing, and adherence to ART in Nepal.
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